- Home
- XPEL vs VERA Comparison
XPEL vs VERA Comparison
Compare XPEL & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPEL | VERA |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | 1337 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 2.8B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XPEL | VERA |
|---|---|---|
| Price | $37.95 | $38.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $81.30 |
| AVG Volume (30 Days) | 254.2K | ★ 928.0K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.12 | N/A |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $476,200,000.00 | N/A |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $11.98 | $445.28 |
| P/E Ratio | $20.51 | ★ N/A |
| Revenue Growth | ★ 13.27 | N/A |
| 52 Week Low | $24.27 | $18.53 |
| 52 Week High | $55.91 | $56.05 |
Technical Indicators
Market Signals| Indicator | XPEL | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 25.36 | 36.82 |
| Support Level | $35.10 | $37.20 |
| Resistance Level | $38.71 | $43.21 |
| Average True Range (ATR) | 1.59 | 2.18 |
| MACD | -0.29 | -0.00 |
| Stochastic Oscillator | 11.80 | 17.47 |
Price Performance
Historical ComparisonAbout XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services principally to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from Product, which includes Paint protection film and Window film. The company derives revenue from Service, which includes Software, Cutbank credits, and Installation labor. The majority of revenue is derived from the United States.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.